Back
ESC2025 Premium Access

Rate vs. rhythm control in patients with transthyretin amyloid cardiomyopathy and atrial fibrillation

Session: Treatment of atrial fibrillation: there is more than ablation
Topic: Antiarrhythmic Drug Treatment
Speaker: Doctor P. Lustig (Vienna, AT)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Paul Lustig

Medical University of Vienna, Vienna (Austria)
0 follower

5 more presentations in this session

Frequency of recurrence following cardioversion of an initial atrial fibrillation episode

Speaker: Doctor K. Usuda (Cambridge, US)

Access
Abstract
Slides
Video
Like
Thumbnail

Joint relevance of CYP2D6 and H558R in the efficacy and toxicity of flecainide in patients with atrial fibrillation: a cohort study.

Speaker: Mr M. Trincado Ave (Santiago de Compostela, ES)

Access
Abstract
Slides
Video
Like
Thumbnail

Efficacy and safety of catheter ablation versus antiarrhythmic drug therapy in ventricular tachycardia management: a systematic review and meta-analysis

Speaker: Doctor L. Lucena (Florianopolis, BR)

Access
Abstract
Slides
Video
Like
Thumbnail

Safety outcomes of catheter ablation versus antiarrhythmic drugs in atrial fibrillation: a comprehensive systematic review and meta-analysis

Speaker: Doctor M. SHAWKI (Melbourne, AU)

Access
Abstract
Slides
Video
Like
Thumbnail

Prevention of atrial fibrillation recurrence with vitamin C during catheter ablation

Speaker: Doctor A. Tian (Beijing, CN)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Treatment of atrial fibrillation: there is more than ablation

Speakers: Doctor P. Lustig, Doctor K. Usuda, Mr M. Trincado Ave, Doctor L. Lucena, Doctor M. SHAWKI...
Access
Video
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources